Sarepta Therapeutics Inc to Discuss 3-Year Topline Functional Results Transcript
Good morning and welcome to Sarepta's Embark Three-year Data Topline Results Call. (Operator Instructions). At this time, I will turn the call over to Doug Ingram, Sarepta's Chief Executive Officer. Please go ahead.
Thank you very much. First, before we begin, I must remind you that we will be making forward-looking statements today. So please review our various public filings for the risks and uncertainties that come when one makes statements like that.
Now, with that, first, thank you all for joining us as we present the three year top-line results from Embark, which is our, the one is Phase 3 pivotal trial. The results from Embark year three are remarkably important.
While we have seen longer-term results in study 101, a small four participant proof of concept study, the results discussed today are the first time in history anyone has measured the disease modifying impact of a gene therapy over a three-year period in a large, well-controlled clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
